Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Reactive rifampicin derivative able to damage transcription complex.

Kozlov M, Nudler E, Nikiforov V, Mustaev A.

Bioconjug Chem. 2013 Mar 20;24(3):443-7. doi: 10.1021/bc3005667. Epub 2013 Mar 1.

PMID:
23425196
2.

Structural mechanism for rifampicin inhibition of bacterial rna polymerase.

Campbell EA, Korzheva N, Mustaev A, Murakami K, Nair S, Goldfarb A, Darst SA.

Cell. 2001 Mar 23;104(6):901-12.

3.

Molecular insights into the mechanism of phenotypic tolerance to rifampicin conferred on mycobacterial RNA polymerase by MsRbpA.

Dey A, Verma AK, Chatterji D.

Microbiology. 2011 Jul;157(Pt 7):2056-71. doi: 10.1099/mic.0.047480-0. Epub 2011 Mar 17.

PMID:
21415119
4.

Structure determination of ribosylated rifampicin and its derivative: new inactivated metabolites of rifampicin by mycobacterial strains.

Morisaki N, Kobayashi H, Iwasaki S, Furihata K, Dabbs ER, Yazawa K, Mikami Y.

J Antibiot (Tokyo). 1995 Nov;48(11):1299-303.

5.

Novel insertion and deletion mutants of RpoB that render Mycobacterium smegmatis RNA polymerase resistant to rifampicin-mediated inhibition of transcription.

Malshetty V, Kurthkoti K, China A, Mallick B, Yamunadevi S, Sang PB, Srinivasan N, Nagaraja V, Varshney U.

Microbiology. 2010 May;156(Pt 5):1565-73. doi: 10.1099/mic.0.036970-0. Epub 2010 Feb 11.

PMID:
20150242
6.
7.

Stationary phase induced alterations in mycobacterial RNA polymerase assembly: A cue to its phenotypic resistance towards rifampicin.

Mukherjee R, Chatterji D.

Biochem Biophys Res Commun. 2008 May 9;369(3):899-904. doi: 10.1016/j.bbrc.2008.02.118. Epub 2008 Mar 6.

PMID:
18328810
8.

Topology of the RNA polymerase active center probed by chimeric rifampicin-nucleotide compounds.

Mustaev A, Zaychikov E, Severinov K, Kashlev M, Polyakov A, Nikiforov V, Goldfarb A.

Proc Natl Acad Sci U S A. 1994 Dec 6;91(25):12036-40.

9.

Progress in targeting bacterial transcription.

Villain-Guillot P, Bastide L, Gualtieri M, Leonetti JP.

Drug Discov Today. 2007 Mar;12(5-6):200-8. Epub 2007 Feb 5. Review.

PMID:
17331884
10.
11.
12.
14.

Transcription modulation of Salmonella enterica serovar Typhimurium promoters by sub-MIC levels of rifampin.

Yim G, de la Cruz F, Spiegelman GB, Davies J.

J Bacteriol. 2006 Nov;188(22):7988-91. Epub 2006 Sep 15.

15.

Mycobacterial mistranslation is necessary and sufficient for rifampicin phenotypic resistance.

Javid B, Sorrentino F, Toosky M, Zheng W, Pinkham JT, Jain N, Pan M, Deighan P, Rubin EJ.

Proc Natl Acad Sci U S A. 2014 Jan 21;111(3):1132-7. doi: 10.1073/pnas.1317580111. Epub 2014 Jan 6.

16.

Structural, functional, and genetic analysis of sorangicin inhibition of bacterial RNA polymerase.

Campbell EA, Pavlova O, Zenkin N, Leon F, Irschik H, Jansen R, Severinov K, Darst SA.

EMBO J. 2005 Feb 23;24(4):674-82. Epub 2005 Feb 3.

17.

Effect of pH, mucin and bovine serum on rifampicin permeability through Caco-2 cells.

Gonçalves JE, Ballerini Fernandes M, Chiann C, Gai MN, De Souza J, Storpirtis S.

Biopharm Drug Dispos. 2012 Sep;33(6):316-23. doi: 10.1002/bdd.1802. Epub 2012 Aug 30.

PMID:
22847250
18.

Mycobacterium tuberculosis RbpA protein is a new type of transcriptional activator that stabilizes the σ A-containing RNA polymerase holoenzyme.

Hu Y, Morichaud Z, Chen S, Leonetti JP, Brodolin K.

Nucleic Acids Res. 2012 Aug;40(14):6547-57. doi: 10.1093/nar/gks346. Epub 2012 May 8.

20.

Supplemental Content

Support Center